Holen Sie sich die Stockscreener-App
49.24
2.61%
-1.32
Handel nachbörslich:
49.50
0.26
+0.53%
Schlusskurs vom Vortag:
$50.56
Offen:
$50.67
24-Stunden-Volumen:
829.65K
Relative Volume:
0.54
Marktkapitalisierung:
$3.93B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-13.13
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
-4.17%
1M Leistung:
-12.37%
6M Leistung:
-4.33%
1J Leistung:
+75.11%
1-Tages-Spanne:
$49.21
$50.69
1-Wochen-Bereich:
$49.21
$52.32
52-Wochen-Spanne:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
49.24 | 4.03B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Teachers Retirement System of The State of Kentucky Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
How strong is Akero Therapeutics Inc. company’s balance sheetFree Daily Trading Room Entry - jammulinksnews.com
What makes Akero Therapeutics Inc. stock price move sharplyMarket Forecast Picks That Work - jammulinksnews.com
Is Akero Therapeutics Inc. a growth stock or a value stockUnlock expert trading strategies for growth - jammulinksnews.com
Jennison Associates LLC Invests $533,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Readystate Asset Management LP Acquires Shares of 100,500 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Lowered by Kennondale Capital Management LLC - MarketBeat
What analysts say about Akero Therapeutics Inc. stockTremendous growth potential - PrintWeekIndia
Is Akero Therapeutics Inc. a good long term investmentFast-track wealth growth - PrintWeekIndia
What drives Akero Therapeutics Inc. stock priceHigh-margin investment plays - PrintWeekIndia
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Bank of New York Mellon Corp - MarketBeat
AstraZeneca’s Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in Subgroup - Insider Monkey
Is Akero Therapeutics Inc. stock a growth or value playFree Trend-Following Techniques - jammulinksnews.com
How to Take Advantage of moves in (AKRO) - news.stocktradersdaily.com
Edgestream Partners L.P. Acquires Shares of 6,947 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - Autocar Professional
5,565 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Xponance Inc. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $529,500.00 in Stock - MarketBeat
257,025 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Principal Financial Group Inc. - MarketBeat
Mirum Gains 35% in 3 Months: How Should You Play the Stock? - The Globe and Mail
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Price Target from Analysts - MarketBeat
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akero Therapeutics Inc-Aktie (AKRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Yale Catriona | Chief Development Officer |
Jul 16 '25 |
Sale |
52.95 |
10,000 |
529,467 |
91,488 |
| Cheng Andrew | President and CEO |
Jul 10 '25 |
Sale |
51.16 |
30,000 |
1,534,895 |
520,757 |
| Rolph Timothy | Chief Scientific Officer |
Jul 07 '25 |
Option Exercise |
21.09 |
12,500 |
263,625 |
179,624 |
| Rolph Timothy | Chief Scientific Officer |
Jul 07 '25 |
Sale |
51.09 |
12,500 |
638,661 |
167,124 |
1.32%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):